NDAORALSOLUTION
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 10m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEZRULY (terazosin) is an oral solution formulation of terazosin, an alpha-1 adrenergic antagonist approved by the FDA on July 29, 2024. The drug is indicated for benign prostatic hyperplasia and hypertension by blocking alpha-1 receptors to relax smooth muscle in the prostate and blood vessels. This novel liquid formulation represents a new delivery option for an established active pharmaceutical ingredient.
Growth14.6 years to LOE
Early-stage product with zero competitive pressure presents opportunity for brand-building and market development roles as the commercial infrastructure scales.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin
Started Apr 2011
24 enrolled
Ejaculation
Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin
Started Mar 2007
23 enrolled
Hyperhidrosis
Career Relevance
TEZRULY is a newly launched product with zero current job postings linked to it, presenting an early-stage opportunity for professionals seeking to build a franchise from launch. Working on this product offers the chance to shape go-to-market strategy, establish market presence, and develop differentiation in an established therapeutic category before competitors respond.
Worked on TEZRULY at Agepha Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.